Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Interferon-alfa (IFN-α) is known to enhance gefitinib's antiproliferative effects in certain solid tumors.
• The interaction between IFN-α and gefitinib in non-small cell lung cancer (NSCLC) with varying genetic profiles requires further investigation.

Purpose of the Study:

• To evaluate the combined effects of IFN-α and gefitinib on NSCLC cell lines (A549, H1299, HCC827).
• To assess the impact of different administration sequences (combination vs. sequential pretreatment) on treatment efficacy.
• To explore the underlying molecular mechanisms, including EGFR and STAT3 signaling pathways.

Main Methods:

• Cell proliferation was assessed using MTT assays.
• Apoptosis was measured via Annexin V/propidium iodide staining and flow cytometry.
• Western blotting was employed to analyze the expression and phosphorylation status of EGFR and STAT3.

Main Results:

• An additive interaction was observed when gefitinib and IFN-α were administered concurrently.
• Sequential administration, with IFN-α pretreatment, resulted in antagonism and reduced gefitinib sensitivity in most cell lines, notably HCC827.
• Both IFN-α and gefitinib inhibited STAT3 phosphorylation, with IFN-α showing a significant inhibitory effect.

Conclusions:

• The findings suggest that IFN-α can modulate gefitinib sensitivity in NSCLC, with the sequence of administration being critical.
• IFN-α's inhibition of STAT3 phosphorylation may play a role in its effects on gefitinib sensitivity.
• EGFR signaling activation might be involved in the observed reduction in gefitinib sensitivity following IFN-α pretreatment in NSCLC cell lines.